Dirk Thye, Quince Therapeutics CEO

Af­ter piv­ot­ing from Alzheimer's to bone con­di­tions, biotech piv­ots again — and halves its head­count

When trou­bled pub­lic biotech Cor­texyme bought a pri­vate start­up named Novos­teo and hand­ed the keys to its ex­ec­u­tive team, the com­pa­ny — which changed its name …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.